LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act, Section 28(a)

Company Announcement no. 31/2008

To: OMX Nordic Exchange Copenhagen	                     Hørsholm, Denmark,
September  11, 2008 


LifeCycle Pharma A/S - Report Pursuant to the Danish Securities Trading Act,
Section 28(a) 

Hørsholm, Denmark, September  11, 2008; Pursuant to the Danish Securities
Trading Act, Section 28(a), LifeCycle Pharma A/S (OMX: LCP) is required on a
daily basis, to make public transactions in LifeCycle Pharma shares and related
securities by persons discharging managerial responsibilities and persons /
companies closely associated with these. 

Name	                   Michael Beckert
Reason for reporting	Chief Medical Officer & EVP
Issuer and ID code/ISIN	LifeCycle Pharma A/S / DK0060048148
Type of transaction	Subscription of shares through exercise warrants
Date of transaction	September 11, 2008
Relevant market	         OMX Nordic Exchange Copenhagen
Number of traded securities	4,735
Market value	          DKK 30,664.81


About LifeCycle Pharma A/S (“LCP”)
LCP is an emerging specialty pharmaceutical company that, through innovative
technologies, is able to rapidly develop a portfolio of differentiated products
to meet the unique needs of key therapeutic markets and patient populations.
This includes products for immunosuppression, specifically organ
transplantation, and to combat certain cardiovascular diseases. By using its
unique and patented delivery technology, MeltDose®, LCP is able to develop
drugs with enhanced absorption and thereby increased bioavailability. LCP has a
cholesterol lowering product, Fenoglide™, currently on the U.S. market and a
diversified near- and medium-term pipeline, including four product candidates
in clinical trials and two in preclinical stages of development. LCP is listed
on the OMX Nordic Exchange Copenhagen under the trading symbol (OMX: LCP). For
further information, please visit www.lcpharma.com. 

For further information, please visit www.lcpharma.com.

 
Contact:
LifeCycle Pharma A/S
Hans Christian Teisen, 
Executive Vice President & CFO
Phone: +45 70 33 33 00
E-mail: HCT@lcpharma.com